In 2025 it will be 20 years since the Centre for Psychedelic Research began its study of psychedelic drugs in humans, first at Bristol University and then since 2008 at Imperial College London. What started out as an imaging study of the brain mechanisms of psilocybin in collaboration with Robin Carhart-Harris and Amanda Feilding has turned into a life changing body of research that has encompassed many hundreds of colleagues: doctors psychologists and neuroscientists.
David Nutt
Patil Armenian, Benjamin Hatten
VA researchers Dr. Chris Stauffer and Dr. Amy Lehrner share insights on their pioneering studies of psychedelic-assisted therapy for PTSD, depression, and substance use in veterans, highlighting clinical models, set and setting, and peer support involvement.
Amy Lehrner, Christopher “Chris” Stauffer
Dráulio Araújo, Fernanda Palhano-Fontes, Marcelo Leite, Nicole Galvão-Coelho
Rupika Delgoda, Kimberly Foster, William Irvine, Isaac Morrison
Depression remains a major unmet medical need globally, with current medications often providing inadequate relief and leading to high costs. Psychedelic therapies, like psilocybin, show promise in revolutionizing mental health
Charles Raison
Dr. Sloshower presents results from a psilocybin-assisted therapy study for major depression, showing larger antidepressant effects than placebo, with lasting mood improvements. Dr. Kilpatrick discusses longitudinal case studies.
Jordan Sloshower, Stephanie Kilpatrick
Study investigates psilocybin's effects on depression and burnout in healthcare clinicians post-COVID frontline work with pre- and post-dose psychotherapy. Trial registration: NCT05163496.
Anthony L Back
Psychedelics are studied for psychiatric disorders; research emphasizes 'set and setting.' Study explores psychosocial factors in psychedelic use, linking communal experiences to improved mental health outcomes.
Hannes Kettner
